wbc related disease part ii
DESCRIPTION
WBC related disease part II. 嘉義基督教醫院 李明陽醫師. WBC disease part II. Malignant lymphoma CLL Plasma cell disorder. LN paracortex. LN medulla. IgM. B-CLL/SLL. Plasmacytoid Lymphocyte . B-immunoblast. Blood Marrow Primary follicle. Precursor B ALL/LBL. Lymphoplasmacytic lymphoma . - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/1.jpg)
WBC related disease part II
嘉義基督教醫院 李明陽醫師
![Page 2: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/2.jpg)
WBC disease part II
Malignant lymphoma CLL Plasma cell disorder
![Page 3: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/3.jpg)
Precursor BLymphoblast Naïve B
ANTIGEN
B-immunoblast
PlasmacytoidLymphocyte
Centrocyte
Plasma cell
Marginal Zone &Monocytoid B cell
Centroblast
LN paracortex LN medulla
BM
Germinal center
BM
BloodMarrowPrimary follicle
Precursor BPrecursor BALL/LBLALL/LBL
B-CLL/SLLB-CLL/SLL
Large B-cell lymphomaLarge B-cell lymphoma
Large B-cell lymphomaLarge B-cell lymphoma
Burkitt’s lymphomaBurkitt’s lymphomat(8;14)t(8;14)
Mantle cell lymphomaMantle cell lymphomat(11;14)t(11;14)
Follicular lymphomaFollicular lymphomat(14;18)t(14;18)
Plasma cellPlasma cellMyelomaMyeloma
LymphoplasmacyticLymphoplasmacyticlymphoma lymphoma
Marginal ZoneMarginal ZoneLymphomaLymphomat(11;18)t(11;18)
CD19CD10TdTCu+
CD23+Bcl-2
Mantle cell
CD23-
IgM+
CD10+Bcl-6
cIgM+CD20+
CD20+,CD5+,sIgM+D+IgM+G+
IgG/ACD20-CD38+
IgM
![Page 4: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/4.jpg)
![Page 5: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/5.jpg)
![Page 6: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/6.jpg)
The Differentiation Stage of B & T-cells Determined the Type of Malignancy
EarlyEarlyPre-BPre-B
Pre-BPre-B Lympho-Lympho-PlasmacytoidPlasmacytoid
PlasmaPlasmacellscells
BMBM
Immuno-Immuno-blastblast
Mature-BMature-B
Y Y Y Y Y Y YY
HCR HCR KR/D λR/D
sIgM sIgM/D sIgM/G/A sIgM/G/A
BMBM Lymph nodes or lymphoid tissuesLymph nodes or lymphoid tissues
Y Y
ProthymocyteProthymocyte Subcapsular TSubcapsular T Cortical TCortical T Medullary T (peripheral T)Medullary T (peripheral T)CD7
CD2CD5CD3
CD1CD4/8
Precursor T-cell leukemia/lymphoma Peripheral T-cell neoplasms
![Page 7: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/7.jpg)
Classification of Lymphoma1982• Working formulation
– Low grade (LG)– Intermediate grade (IG)– High grade (HG)
1994• Revised European-American
Lymphoma (REAL)– Emphasize Immunopheno
type
2001WHO classification
![Page 8: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/8.jpg)
WHO Hisological Classification of B-cell Neoplasms
• Precursor B Lymphoblastic leukemia/lymphoma
• Mature B Chronic lymphocytic leukemia/Small lymphocytic lymphoma Pro-lymphocytic leukemia Lymphoplasmacytic lymphoma Splenic marginal zone B lymphoma Hairy cell leukemia Plasma cell myeloma Monoclonal Gammopathy of undetermined Significance (MGUS) Solitary plasmacytoma of bone Extraosseous plasmacytoma Primary amyloidosis Heavy chain diseases
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) Nodal marginal zone B-cell lymphoma Follicular lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma Mediastinal (thymic) large B-cell lymphoma Intravascular large B-cell lymphoma Primary effusion lymphoma Burkitt lymphoma/leukemia
• B-cell proliferations of uncertain malignant potential
Lymphomatoid granulomatosis PTLD, polymorphic
![Page 9: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/9.jpg)
WHO Histological Classification of T-cell and NK-cell Neoplasms
• Leukemic/disseminated T-cell prolymphocytic leukemia T-cell large granular lymphocytic le
ukemia Aggressive NK cell leukemia Adult T-cell leukemia/lymphoma
• Cutaneous Mycosis fungoides Sezary syndrome Primary cutaneous anaplastic large
cell lymphoma Lymphomatoid papulosis
• Other extranodal Extranodal NK/T cell lymphoma, na
sal type
Enteropathy-type T-cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-c
ell lymphoma
• Nodal Angioimmunoblastic T-cell lympho
ma Peripheral T-cell lymphoma, unspe
cified Anaplastic large cell lymphoma
• Neoplasm of uncertain lineage and stage of differentiation
Blastic NK cell lymphoma
![Page 10: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/10.jpg)
Cellular Origin of Lymphoma
U.S. &U.S. &EuropeEurope
TaiwanTaiwan
B-lymphocytesB-lymphocytes80~85%80~85%
B-lymphocytesB-lymphocytes55~60%55~60%
T-lymphocytesT-lymphocytes13~14%13~14%
T-lymphocytesT-lymphocytes40~45%40~45%
NK-cellsNK-cells1~2%1~2%
NK-cellsNK-cells?%?%
NHLNHL
Immune deficiency
Autoimmune disorder
Infection
Possible Possible etiologiesetiologies
Autoimmune disorder
Infection ?
HLHL
?
30%
10%
![Page 11: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/11.jpg)
• Diffuse large B-cell lymphoma 30.6%• Follicular lymphoma 22.1%• MALT lymphoma 7.6%• Chronic Lymphocytic LeukemiaL/SLL 6.7%• Mantle cell lymphoma 6.0%• Mediastinal large B-cell lymphoma 2.4%• Burkitt’s lymphoma 2.5%• Nodal marginal zone lymphoma 1.8%• Lymphoplasmacytic lymphoma 1.2%• Mature T-cell lymphomas 7.6%• Anaplastic large cell lymphoma 2.4%• Precursor T lymphoblastic 1.7%• Other types 7.4%
Frequency of B and T/NK Cell Lymphoid Malignacies (WHO)
![Page 12: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/12.jpg)
•Symptoms and signs•Lymphadenopathy•Fever•Body weight loss•Night sweat•Organ-specific
•Diagnosis•Biopsy for Pathological exam
•Staging work up
![Page 13: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/13.jpg)
Staging of HLStaging of HL(Cotswold revision of the Ann Arbor staging classification)(Cotswold revision of the Ann Arbor staging classification)
Stage DefinitionI Involvement of a single lymph node or lymphoid structure (e.g., spleen, thymus, Waldeyer’s ring)II Involvement of two or more lymph node regions on
the same side of the diaphragm; the number of anatomic sites should be indicated by suffix (e.g., II3)
III Involvement of lymph node regions or structures on both sides of the diaphragm
IV Diffuse or disseminated involvement of one or more distant extranodal organ with or without associated lymph node involvement, Involvement of extranodal site(s) beyound those designated EA, no symptoms; B, fever/sweats/weight loss; X, bulky disease:>1/3 widening of the mediastinum at T5-6, or maximun of nodal mass>10cmE, involvement of a single extranodal site
![Page 14: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/14.jpg)
A: no symptomsB: fever/sweats/weight loss; X: bulky disease:>1/3 widening of the mediastinum at T5-6, or maximun of nodal mass>10cmE: indicates extranodal involvement adjacent to an involved lymph node (eg,
disease of mediastinal nodes and hilar adenopathy with adjacent lung infiltration is classified as stage IIE)
![Page 15: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/15.jpg)
International Prognostic Index for NHLFive clinical risk factors: 1. Age > 60 years 2. Serum LDH elevated 3. Performance status > 2 (ECOG) or < 70 (Karnofsky) 4. Ann Arbor stage III or IV 5. >1 site of extranodal involvementPatients are assigned a number for each risk factor they havePatients are grouped differently based upon the type of lymphomaFor diffuse large B cell lymphoma: 0,1 factor = low risk: 35% of cases; 5-year survival, 73% 2 factors = low-intermediate risk: 27% of cases; 5-year survival, 51% 3 factors = high-intermediate risk: 22% of cases; 5-year survival, 43% 4,5 factors = high risk: 16% of cases; 5-year survival, 26%
![Page 16: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/16.jpg)
![Page 17: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/17.jpg)
Treatment Gold standard:Systemic chemotherapy
Combination chemotherapyCHOPm-BACODESHAPBOMESBEAM (myeloablative)+Autologous stem cell transplantationPurine analogue
Fludarabine
•anti-CD20 (Rituximab)•anti-CD20 radioimmunoconjugates:
•Y (Yttrium)-90 ibritumomab tiuxetan (Zevalin)•I-131 tositumomab (Bexxar
anti-CD52 (Alemtuzumab, Campath-1H)
Radiotherapy13-cis-Retinoid acid
![Page 18: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/18.jpg)
WHO Histological Classification of Hodgkin Lymphoma
• Nodular lymphocyte predominant HL (NLPHL)
• Classical HL (CHL)Nodular sclerosis classical HL (NSCHL)Mixed cellularity classical HL (MCCHL)Lymphocyte-rich classical HL (LRCHL)Lymphocyte-depleted classical HL (LPCHL)
![Page 19: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/19.jpg)
Common Clinical Characteristics of Hodgkin Lymphoma
• Neck lymphadenopathy
• Young adult
• Hodgkin and Reed-Sternberg cells (HRS)
• Rich inflammatory backgroud
![Page 20: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/20.jpg)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Monomorphic small and round B-lymphocytes in PB/BM/LN
• Median age of 65• Male/female=2/1• Most asymptomatic• Transform to DLBCL (Richte
r syndrome), 3.5%• Rai classification (stage I, II, III, IV) or Binet cl
assification ( stage A,B,C)
• Trisomy 12 and 13q, 14q abnormality
• CD5 (+), CD 23(+)• Indolent but incurable• Median OS, 7 years• Survival : normal karyotype
> trisomy 12 > 13 q > 14q
![Page 21: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/21.jpg)
Stage Clinical FeaturesMedian
Survival,Years
RAI System0: Low risk Lymphocytosis only in blood and marrow >10
I: Intermediate riskLymphocytosis + lymphadenopathy +splenomegaly ± hepatomegaly 7
II
III: High risk Lymphocytosis + anemia 1.5IV Lymphocytosis + thrombocytopenia
Binet System
AFewer than three areas of clinicallymphadenopathy; no anemia orthrombocytopenia
>10
BThree or more involved node areas; noanemia or thrombocytopenia 7
CHemoglobin 10 g/dL and/or platelets<100,000/l 2
![Page 22: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/22.jpg)
Lymphoplasmacytic Lymphoma/Waldenström macroglobulinemia
• Lymphoplasmacytic lymphocytes in PB/BM/LN/Spleen
• Serum M-protein with hyperviscosity and cryoglobulinemia
• 1.5%, male predominant• Organomegaly, coagulopathy,
neuropathy, plasmapheresis/ exhange should be considered
• Association with HCV infection• DDX with CLL, marginal zone l
ymphoma (MALToma) and follicular lymphoma
• Rearrangement of PAX-5 gene; t(9;14)• Indolent course• Aged, advanced stage, cytopen
ias, neuropathy, weight loss have poor prognosis
![Page 23: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/23.jpg)
Plasma cell Myeloma
• Plasmacytosis• Osteolysis• M-protein• Nephropathy• Incurable
![Page 24: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/24.jpg)
Plasma cell Myeloma-Natural History
Time (yr)
Tumor
burden
MGUS
Diagnosis
TreatmentPlateau
Acceleration
0-2-5
TxM+PVAD
HDCT with AutoPBSCT
II3 7
IgG 40%IgA 25%Light-chain 20%Others 15%
Poor prognostic factor Monosomy 13 or 13q- Hypodiploidy
![Page 25: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/25.jpg)
Bortezomib phase III trail• APEX ( Assessment of Proteasome Inhibition for
Extending Remissions)• 669 patients enrolled: randomly received either
dexamethasone or bortezomib• Bortezomib showed significantly increased
survival rates among patients (80%) after 1 year, dexamethasone (66%)
• 38% response rate for bortezomib• 18% response rate for dexamethasone
![Page 26: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/26.jpg)
Bortezomib as a Model Drug• First proteasome inhibitor • Inhibits 26S proteasome: principle regulator of
intracellular protein degradation• The proteasome normally degrades IKB which
activates NFKB which then promotes cell survival, stimulates growth, makes cells resistant to apoptosis and importantly induces drug resistance in myeloma cells
• Bortezomib prevents all from happening by inhibiting the proteasome
![Page 27: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/27.jpg)
in Mantle Cell Lymphoma• Cancerous cells growing out of control in the
lymph nodes• Accounts for only 6% of the non-Hodgkin’s
lymphomas• December 6, 2006 FDA approved bortezomib for
treatment of patients with mantle cell lymphoma who have received at least one prior therapy
• Overall response rate 31%• Complete responses 8%• Median response duration 15.4 months
![Page 28: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/28.jpg)
Non-Hodgkin Lymphoma
![Page 29: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/29.jpg)
Diffuse Large B-cell Lymphoma
• Large B lymphoid cells • Broad age distribution• Male/female=1/1• Nodal (60%) vs. extranoda
l (40%)• Extranodal, common in GI
(stomach or ileocoecal region), and any sites elsewhere
• Pan-B markers, CD5(-), CD10(-)
• Ki-67+/bcl-6+
• Recently, a molecular typing by using microarrays: GC-B (better outcome) vs. activated B (worse outcome)
• Aggressive course, potentially curable
• International Prognostic Index (Age, LDH, PS, Stage, Extra-LN)
![Page 30: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/30.jpg)
Burkitt Lymphoma
• An aggressive B-cell lymphoma with frequent extranodal involvement and leukemic change (L3/ALL)
• Children & young adults with male predominance
• Jaws and facial bones in endemic BL, abdominal masses in sporadic BL; rare nodal involvement
• CNS involvement is quite common• Short doubling time of the tumor
• Infectious rates of EBV (co-factor)• Abnormalities of cMYC gene (8q24)
play an essential role• t(8;14), t(2;8), t(8;22)• CD5(-), CD10(+), Pan B Ag(+)• Highly aggressive, potentially curabl
e after high dose C/T
![Page 31: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/31.jpg)
B-lymphoblastic lymphoma Distinguish from ALL :
PB invlvement (-) BM: < 25% blastExtramedullary tumor donimantTdT(+) , CD 10+, CD 34+ , CD19+ t(9.22) poor outcome
![Page 32: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/32.jpg)
Follicular Lymphoma
• Follicular centre B cells• Median age of 59 years• Male/female=1:1.7• Nodal disease, also in
Spleen/PB/BM(40%)• Histology pattern:
follicular(>75%), follicular and diffuse(25~75%), minimally follicular(<25%)
• Histology grade I ,grade II , grade III • Transform to diffuse large B-cell lymp
homa is occassionally seen• Rearrangement of Ig with extensive s
omatic mutations and intraclonal diversity (GC cells)
• t(14;18)(most cases)(BCL-2 overexpression) & t(2;18)(less cases)
![Page 33: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/33.jpg)
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
(MALT lymphoma)
• Extranodal B-lymphoma with heterogenous* B lymphocytes
• GI tract(50%), followed by lung, head and neck, ocular, skin, thyroid, and breast epithelial associated
• Median age of 60 years• Male/female=1:1.2
• Association of chronic inflammation, infections, (Helicobacter pylori, Borrelia burgdorferi) autoimmune diseases
• Antibiotics treatment, chemotherapy, surgical intervention
*. Small lymphocytes, centrocytes, monocytoid, centroblasts, immunoblasts, plasmacytoid lymphocytes
![Page 34: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/34.jpg)
Nodal Marginal Zone B-cell Lymphoma
• Expansion of marginal zone B (mostly monocytoid) cells without evidence of extranodal or splenic involvement
• Uncommon• Rare trisomy 3 and t(11;1
8) as seen in MALToma
• Indolent lymphoma• Poor response to chemoth
eray• Median OS, 5 years
![Page 35: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/35.jpg)
Splenic Marginal Zone Lymphoma• Small lymphocytes involve the
red and white pulp, with some transformed large cells, and with/without circulating polar villous lymphocytes
• Male/female=1/1• Age>50 years• Involvement of spleen/BM/PB,
rarely LN• M-protein (30%)
• Splenomegaly, autoimmune anemia or thrombocytopenia
• Deletion of 7q21-32• Trisomy 3 and t(11;18) in extra
nodal MZL, but not in SMZL• Indolent course, poor response
to chemotherapy• Splenctomy is considered
![Page 36: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/36.jpg)
Hairy Cell Leukemia• Small B lymphoid cells with ov
al nuclei, abundant cytoplasms with hairy projections in BM/Spleen red pulp/PB
• 2% of lymphoid leukemia• Median age of 55 years• Male/female=5/1• Splenomegaly, pancytopenia
with monocytopenia, infections, vasculitis and immune dysfunction
• BM histology, “fried egg” appearance and reticulin fibrosis
• HCL variant• Purine analogues (2-chlorod
eoxyadenosine, deoxycoformycin, IFN, and splectomy are the choice of treatment
![Page 37: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/37.jpg)
Mantle Cell Lymphoma
• Small to medium sized lymphocytes resemble the centrocytes/FCC, with absence of transformed cells seen in FL
• Median age of 60 years• Male/female=2/1• LN/SN/BM/GI/
Waldeyer’s ring/PB
• Rearrangement of Ig without somatic mutations (pre-GC cells)
• t(11;14)(q13;q32)– IgH/CYCLIN D1
• Blastoid variant (classic vs. pleomorphic) with aggressive course
• Incurable with median OS, 3~5 years if no aggressive tx
![Page 38: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/38.jpg)
Mediastinal (thymic) Large B-cell Lymphoma
• A subtype of DLBCL, arising from mediastinum of putative thymic B-cell origin
• 30~40 years with female predominance
• Large anterior mediastinal masses, dissemination will occur
• EBV-
• Large B lymphoid cells in remnant thymic tissues with compartmentalising fibrosis
• CD19+/CD20+/CD10-/CD5-/CD30±/CD45+
• Overexpression of REL gene (9p) and MAL gene
• Lack of bcl-2, bcl-6, & MYC• Good response to C/T±R/T• Px, dependent on initial stage
![Page 39: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/39.jpg)
Intravascular Large B-cell Lymphoma
• A subtype of extranodal DLBCL limited in the small vessels
• No known epidemiology (adults only till now)
• Widely disseminated in extranodal sites at presentation
• Symptoms of skin and CNS, variable organ involvements
• CD45+/CD20+/CD19+/CD22+/CD79a+
• Aggressive lymphoma and poor response to chemotherapy
![Page 40: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/40.jpg)
Primary Effusion Lymphoma
• Body cavity (serous)-based lymphoma
• HHV-8• Immunodeficiency (HIV+)• Rare• EBV (co-infected)• Immunoblastic, Plasmablastic,
Anaplastic• CD45+/CD19-/CD20-/CD79a-
/CD30+ /CD38+/CD138+/c&sIg-
• Germinal or Post-germinal center B cell (? Some from naïve B cells
• Poor prognosis(< 6m) despite the chemotherapy
• Antiviral treatment and proteosome inhibitors
![Page 41: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/41.jpg)
CD5 CD23 FMC7
cyclinD1
CD10
CD103 CD11c
CD38 CD43 Remark
BL - - - + - - +/- Bcl-6+/CD45+/Ki-67 100%
FL - - - ++ - - - +/- Bcl-2+
MCL
++ - + ++ - - - - + Bcl-2+
CLL ++ ++ - - - - - -
HCL - - + +/- - ++ ++ -
SML - - - - - +/- - - CD21+/CD35+
Surface Marker Analysis of B-Lymphoid Malignancy
![Page 42: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/42.jpg)
T cell lymphoma/leukemia
![Page 43: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/43.jpg)
Precursor T lymphoblastic leukemia/lymphoma
• T-lymphoblasts in PB/BM(T-ALL, 15% of ALL), in nodal or extranodal sites(T-LBL, 90% of LBL)
• High counts and mediastinum or tissue masses
• TdT+/cCD3+/CD2+/CD7+/ CD5+/CD1a+/CD4+CD8+
• Rearrangement of TCRαandδ(14q11),β(7q35), and γ(7p15), with partners of MYC(8q24), TAL1(1p32), RBTN1(11p15), RBTN2(11p13), and HOX11(10q24)
• Rather unfavorable clinical outcome than B-ALL/LBL
![Page 44: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/44.jpg)
T-cell Prolymphocytic Leukemia
• T-PLL, rare• Hepatosplenomegaly, lymphad
enopathy with cytopenias, skin involvement in 20%
• Small to median-sized lymphocytes with cytoplasmic protrusions or blebs
• TdT-/CD1a-/CD2+/CD3+/CD7+/CD4+8(60%),CD4+8+(25%), CD4-8-(15%)
• t(14;14)(q11;q32)• Aggressive course• Median OS < 1 year • CAMPATH-1 responsive
![Page 45: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/45.jpg)
Aggressive NK-cell Leukemia
• NK-cell proliferation• Rare, but more prevalent in Asians• Teenagers with male predominanc
e• PB/BM/LV/SN• Fever, constitutional symptoms, a l
eukemic blood picture, coagulopathy, and hemophagocytic syndrome, as well as organ failure
• EBV+/hypersensitivity to mosquito bites
• CD2+/CD3-/CD56+/CD11b±/CD16 ±/CD57-
• No TCR rearrangement• Rapid progress with fatal outcome
within 1~2 years
![Page 46: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/46.jpg)
Adult T-cell Leukemia/Lymphoma• HTLV-1 related peripheral T-cell (fl
ower cells) neoplasm• Endemic in Japan• Median age of 55 years with male/
female=1.5/1• PB/BM/LN/Skin(Pautrier-like micro
abscess)• Acute, lymphomatous, chronic and
smoldering variants• P40 tax viral protein leads to trans
criptional activation of many genes in the HTLV-1+ lymphocytes
• CD2+/CD3+/CD5+/CD25++• CD7-/CD4+CD8-(rare, CD4-CD8+)• Clinical subtypes, performance status,
age, Ca, LDH levels are prognostic factor
• In acute form, median OS=1~2yrs• Treatment choice: INF + AZT +C/T(?)
![Page 47: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/47.jpg)
Extranodal NK/T-cell Lymphoma, nasal type
• More prevalent in Asia, Mexico, Central and South America
• Adults and male predominant • Extranodal presentations• Nasal obstruction, epistaxis du
e to locally advanced tumor mass
• Dissemination will occur during the clinical course
• Strong association with EBV in Asians
• Angiocentric, angiodestructive with coagulative necrosis
• CD2+/sCD3-/CD56+/cCD3+/granzyme B+/TIA-1+/perforin+
• CD4CD8/CD5/TCR/CD16/CD57/CD43/CD45RO are all negative
• TCR rearrangement, germline• Variable clinical courses, limite
d vs. disseminated
![Page 48: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/48.jpg)
Mycosis fungoides• Mature T-cell lymphoma presen
ting in skin• Small to medium-sized cells wit
h cerebriform nuclei• Adults/elderly, male/female=2/1• Skin, extracutaneous dissemin
ation may occur• Initial patches, plaques on the t
runk
• Epidermotropic infiltration with Pautrier microabscess, and dermal infiltration
• CD2+/CD3+/CD5+/CD4+/CD8-• CD7-/HECA antigen+• Clinical stage, the most importa
nt prognostic factorStage characteristicsIa Skin, limited patches/plaquesIb Skin, disseminated lesionsIc Skin, tumor formationII LN enlargement, histology –III LN enlargement, histology +IV Visceral dissemination
![Page 49: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/49.jpg)
Angioimmunoblastic T-cell Lymphoma(ALIT)
• PTCL, systemic involvement with proliferation of endothelial venules and follicular dendritic cells (CD21+ cells)
• Middle age, male/female=1:1• Generalized LAPs, hepatospl
enomegaly, and skin rashes, BM is commonly involved
• Advanced stage at diagnosis, systemic symptoms, and hypergammaglobulinemia, serositis with effusions
• EBV+ in adjacent B cells (>75% cases)
• T-zone hyperplasia of LN, with a lot of reactive cells, included transformed immunoblastic B cells, and esp. FDCs
• CD2+/CD3+/CD5+/CD4+CD8+/CD7-
• Aggressive course with a median OS < 3 years
![Page 50: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/50.jpg)
Peipheral T-cell Lymphoma, unspecified
• Half of the PTCL in Western countries
• Adults, male/female=1/1• LN/LV/Spleen/Skin• Systemic symptoms and par
aneoplastic features
• Lymphoepithelioid cell variant (Lennert lymphoma)
• CD2+/CD3+/CD5+/CD4+CD8-/CD30±
• Complex cytogenetic changes, trisomy 3
• Poor prognosis, 5-yr SR=20~30%
• Clinical stage and IPI, as prognostic factors
![Page 51: WBC related disease part II](https://reader036.vdocuments.site/reader036/viewer/2022062501/5681675c550346895ddc26f4/html5/thumbnails/51.jpg)
Anaplastic Large Cell Lymphoma
• T-cell lymphoma (TCR rearrangement+)
• Large lymphocytes with abundant cytoplasm and pleomorphic (horse-shoe) nuclei
• ALK+ALCL, young age with male/female=6.5
• ALK-ALCL, elder age with male/female=0.9
• LN and extranodal sites of skin, bone, soft tissue, lung, liver and BM (more common in ALK+ALCL)
• CD30+/cytotoxic granule-associated proteins+/ALK protein+, by t(2;5)[ALK/NPM]
• CD2+/CD4+/CD3±/EMA+/CD15-• Common variant, lymphohistiocyti
c variant and small cell variant• DDX with HL and primary cutaneo
us CD30 positive T-cell lymphoproliferative disorders, c-ALCL & lymphomatoid papulosis
• IPI and ALK, as clinical prognostic factors (ALK+ vs. ALK-, 5 yr-SR=80% & 40% respectively